AMT-130 Well-tolerated Up to a Year in First Two Patients Treated

AMT-130 Well-tolerated Up to a Year in First Two Patients Treated

314727

AMT-130 Well-tolerated Up to a Year in First Two Patients Treated

AMT-130, an investigational gene therapy for the treatment of Huntington’s disease, was overall well-tolerated up to a year after treatment in the first patients to receive the therapy in a clinical trial. The new data, announced by AMT-130’s developer uniQure, cover the first four participants in a Phase 1/2 trial (NCT04120493). Two of them received a low dose of the experimental treatment, and the other two got a sham procedure. So far, no serious adverse events…

You must be logged in to read/download the full post.